Log in

NASDAQ:NVIVInvivo Therapeutics Stock Price, Forecast & News

-0.06 (-3.85 %)
(As of 05/26/2020 04:00 PM ET)
Today's Range
Now: $1.50
50-Day Range
MA: $1.48
52-Week Range
Now: $1.50
Volume404,876 shs
Average Volume563,114 shs
Market Capitalization$7.28 million
P/E RatioN/A
Dividend YieldN/A
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. has research collaboration with the Q Therapeutics, Inc. for the evaluation of the combination of PLGA-PLL based Neuro-Spinal Scaffold with adult neural progenitor cells, including those from induced pluripotent stem cells. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.
Read More
Invivo Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.69 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:NVIV



Sales & Book Value

Annual SalesN/A
Book Value$1.97 per share


Net Income$-11,830,000.00


Market Cap$7.28 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive NVIV News and Ratings via Email

Sign-up to receive the latest news and ratings for NVIV and its competitors with MarketBeat's FREE daily newsletter.

Invivo Therapeutics (NASDAQ:NVIV) Frequently Asked Questions

How has Invivo Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Invivo Therapeutics' stock was trading at $1.60 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NVIV shares have decreased by 6.3% and is now trading at $1.50. View which stocks have been most impacted by Coronavirus.

When is Invivo Therapeutics' next earnings date?

Invivo Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Invivo Therapeutics.

How were Invivo Therapeutics' earnings last quarter?

Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) issued its quarterly earnings results on Wednesday, May, 13th. The biotechnology company reported ($2.47) earnings per share (EPS) for the quarter. View Invivo Therapeutics' earnings history.

When did Invivo Therapeutics' stock split? How did Invivo Therapeutics' stock split work?

Shares of Invivo Therapeutics reverse split on Wednesday, February 12th 2020. The 1-30 reverse split was announced on Monday, February 3rd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 11th 2020. An investor that had 100 shares of Invivo Therapeutics stock prior to the reverse split would have 3 shares after the split.

Has Invivo Therapeutics been receiving favorable news coverage?

Press coverage about NVIV stock has been trending very positive recently, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Invivo Therapeutics earned a daily sentiment score of 4.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutInvivo Therapeutics.

Are investors shorting Invivo Therapeutics?

Invivo Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 46,200 shares, an increase of 82.6% from the April 30th total of 25,300 shares. Based on an average daily trading volume, of 604,600 shares, the short-interest ratio is presently 0.1 days. Currently, 1.0% of the shares of the company are sold short. View Invivo Therapeutics' Current Options Chain.

Who are some of Invivo Therapeutics' key competitors?

What other stocks do shareholders of Invivo Therapeutics own?

Who are Invivo Therapeutics' key executives?

Invivo Therapeutics' management team includes the following people:
  • Dr. Richard M. Toselli, Pres, CEO, Chief Medical Officer & Director (Age 61)
  • Dr. Robert S. Langer Jr., Co-Founder & Member of Scientific Advisory Board (Age 70)
  • Dr. Joseph Philip Vacanti, Co-Founder (Age 70)
  • Mr. Richard C. Christopher, Chief Financial Officer (Age 49)
  • Mr. William D'Agostino PE, Sr. VP of Operations

What is Invivo Therapeutics' stock symbol?

Invivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."

Who are Invivo Therapeutics' major shareholders?

Invivo Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Sabby Management LLC (0.67%), Wedbush Securities Inc. (4.82%) and Perkins Capital Management Inc. (3.53%). View institutional ownership trends for Invivo Therapeutics.

Which major investors are selling Invivo Therapeutics stock?

NVIV stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc.. View insider buying and selling activity for Invivo Therapeutics.

Which major investors are buying Invivo Therapeutics stock?

NVIV stock was purchased by a variety of institutional investors in the last quarter, including Sabby Management LLC, and Wedbush Securities Inc.. View insider buying and selling activity for Invivo Therapeutics.

How do I buy shares of Invivo Therapeutics?

Shares of NVIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Invivo Therapeutics' stock price today?

One share of NVIV stock can currently be purchased for approximately $1.50.

How big of a company is Invivo Therapeutics?

Invivo Therapeutics has a market capitalization of $7.28 million. Invivo Therapeutics employs 6 workers across the globe.

What is Invivo Therapeutics' official website?

The official website for Invivo Therapeutics is www.invivotherapeutics.com.

How can I contact Invivo Therapeutics?

Invivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-863-5500 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.